In the past year, significant changes have occurred regarding diabetes and weight-loss drugs like Novo Nordisk’s Ozembic/Wegovy and Eli Lilly’s Mounjaro/Zepbound. The FDA's decision to lift a shortage declaration has prohibited compounders from selling these branded drugs in bulk, impacting telehealth firms that previously benefited from alternative offerings. Concurrently, a conflict has emerged between Eli Lilly and Empower Pharmacy, which markets its own version of the weight-loss drug Ozembic, leading to concerns about competition and market practices in the burgeoning weight-loss market.
The lifting of the FDA shortage declaration on branded diabetes drugs has ended the ability of compounders to sell in bulk, impacting revenues significantly.
Eli Lilly's Mounjaro and Zepbound now face a dispute with Empower Pharmacy, which offers similar weight-loss injections, raising concerns about market competition.
Collection
[
|
...
]